In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes

Cancer Chemother Pharmacol. 1996;37(5):435-44. doi: 10.1007/s002800050409.

Abstract

A lipophilic cisplatin derivative, cis-bis-neodecanoato-trans- R,R-1,2-diaminocyclohexane platinum (II) (NDDP), was formulated in liposomes composed of phosphatidylcholine (PC) and cholesterol (Chol) additionally containing monosialoganglioside (Gm1) or polyethyleneglycol conjugated to phosphatidylethanolamine (PEG-PE). These NDDP-containing long-circulating liposomes were examined for in vivo antitumor activity using the mouse RIF-1 solid tumor as a target residing outside the reticuloendothelial system (RES). Biodistribution studies, using C3H/HeJ mice and 111In-labelled DTPA-SA as a lipid marker, showed that the activity of GM1 and PEG-PE in prolonging the circulation times of liposomes was preserved in the presence of 3.0 mol% of NDDP in the liposome membranes. The high levels of liposomes remaining in the blood for PC/Chol/GM1 and PC/Chol/PEG3000-PE liposomes were associated with high levels of platinum in the blood as determined by atomic absorption spectrophotometry. These NDDP-containing long-circulating liposomes showed approximately a three-fold increase in tumor accumulation as compared to the conventional PC/Chol liposomes. In vitro cytotoxicity studies using RIF-1 tumor cells showed that the presence of PEG-PE, but not Gm1, significantly enhanced the cytotoxicity of liposomal NDDP. RIF-1 tumor-bearing C3H/HeJ mice were treated twice with 25 mg/kp NDDP in various liposomal formulations on days 12 and 16 after tumor cell inoculation. A significant reduction in the tumor growth rate was observed when NDDP was formulated in PC/Chol/PEG3000-PE liposomes which support both efficient tumor accumulation and enhanced cytotoxicity of liposomal NDDP. On the other hand, NDDP formulated in PC/Chol/GM1 liposomes, which display only a high tumor accumulation, had no effect on the tumor growth rate. Furthermore, NDDP formulated in dimyristoylphosphatidylglycerol (DMPG)-containing liposomes, exhibiting in vitro cytotoxicity comparable to NDDP formulated in PC/Chol/PEG3000-PE liposomes, but showing poor tumor accumulation, was also not effective. These results indicate a potential effectiveness of NDDP formulated in PEG-PE-containing liposomes for therapy of tumors in non-RES organs.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Cell Survival / drug effects
  • Cholesterol
  • Drug Carriers
  • Female
  • Fibrosarcoma / drug therapy*
  • Fibrosarcoma / metabolism
  • Fibrosarcoma / pathology
  • G(M1) Ganglioside
  • Liposomes
  • Mice
  • Mice, Inbred C3H
  • Neoplasm Transplantation
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / pharmacokinetics
  • Organoplatinum Compounds / pharmacology*
  • Organoplatinum Compounds / therapeutic use
  • Phosphatidylcholines
  • Phosphatidylethanolamines
  • Platinum / analysis
  • Polyethylene Glycols
  • Solubility
  • Time Factors
  • Tissue Distribution

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Liposomes
  • Organoplatinum Compounds
  • Phosphatidylcholines
  • Phosphatidylethanolamines
  • bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II)
  • dioleoyl-N-(monomethoxypolyethylene glycol succinyl)phosphatidylethanolamine
  • G(M1) Ganglioside
  • Polyethylene Glycols
  • Platinum
  • Cholesterol